The Journal of Practical Medicine ›› 2023, Vol. 39 ›› Issue (13): 1724-1728.doi: 10.3969/j.issn.1006⁃5725.2023.13.023

• Reviews • Previous Articles    

Research progress of m6A modification in glioma 

GUO Yansong,LI Sirou,LI Lin,ZENG Zhaomu,BAI Zetong,WEN Xichao,ZHENG Kebin.    

  1. Department of Neurosurgery,Affiliated Hospital of Hebei University,Baoding 071000,China 
  • Online:2023-07-10 Published:2023-07-10
  • Contact: ZHENG Kebin E⁃mail:zhengkebinzkb@163.com

Abstract:

Glioma is a tumor of the central nervous system,mainly derived from glial cells. Currently, surgical resection combined with radiotherapy,chemotherapy,electric field therapy and other comprehensive thera⁃ pies are used in clinical practice. However,glioma is difficult to be completely removed,and it is easy to escape from the primary tumor and pass through the brain tissue,leading to relapse and even death of patients. N6⁃methyl⁃ adenine(m6A)gene modification is widely distributed in eukaryotic cells as post ⁃transcriptional modification of mRNA. The modification process is completed by a series of proteins,which can be divided into methyltransferase, demethylase and binding protein according to the different roles of proteins in the methylation process. Dynamic and reversible m6A modification affects the biological behaviors of glioma,such as the occurrence and develop⁃ ment,invasion and metastasis,and angiogenesis. In addition,it plays a clinical role in the diagnosis,treatment and prognosis assessment for glioma. This article reviews the biological effects and applications of m6A modification in glioma,providing a new idea for the treatment of glioma. 

Key words: glioma, N6?methyladenine gene modification, protein, therapeutic target, biomarker